Investors & Media
Company Overview
Kaleido Biosciences is a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the microbiome to treat disease and improve human health. The Company has built a proprietary product platform to enable the rapid and cost-efficient discovery and development of novel Microbiome Metabolic Therapies (MMT™). MMTs are designed to modulate the metabolic output and profile of the microbiome by driving the function and distribution of the gut’s existing microbes. Kaleido is advancing a broad pipeline of MMT candidates with the potential to address a variety of diseases and conditions with significant unmet patient needs.
Click here to view our Corporate Presentation.
Copyright West LLC.
Minimum 15 minutes Delayed.
Minimum 15 minutes Delayed.
Press Releases
Jan 14, 2021
Jan 05, 2021
Jan 04, 2021
Events
Jan 14, 2021 at 2:00 PM EST
Nov 30, 2020 at 10:00 AM EST
Sep 16, 2020 at 12:30 PM EDT
SEC Filings